LENZ Expands Eye Drug Reach

LENZ Therapeutics, Inc. (NASDAQ: LENZ ) on Wednesday announced an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. S. market.

Read Also: New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug Arrotex Secures Exclusive Commercialization Rights Arrotex will receive exclusive rights to register and commercialize VIZZ (aceclidine ophthalmic solution) for the treatment of presbyopia in Australia and New Zealand. In return, LENZ will receive an upfront payment from Arrotex, along with a significant share of the gross margin generated from product sales. Financial details of the agreement were not disclosed.

Arrotex, described by the companies as Australia’s largest and most diversified pharmaceutical company, offers a broad portfolio of prescription medicines across multiple therapeutic categories. S. 44%, which the company says is the first and only FDA-approved aceclidine-based eye drop for presbyopia. S.

Food and Drug Administration approved VIZZ in July 2025 for presbyopia, natural, age-related loss of the eye’s ability to focus on close objects. S. in October 2025. S.

S. , as that remains the largest market opportunity. Analyst Hanbury-Brown said that VIZZ has a best-in-class profile for the large, untapped market of presbyopia. While prior launches in the space have been unsuccessful, William Blair says VIZZ’s differentiated efficacy and durability position it well for success.

Despite somewhat flat implied prescription growth in the first half of the year, the drug is still early in the launch and has yet to see the impact of its DTC campaign. William Bair expects VIZZ to hold blockbuster potential and rates the stock Outperform. 72 at the time of publication on Wednesday, according to Pro data. Image via Shutterstock/ Rulo Jmp Read Also: United Is About To Join American Airlines In An Exclusive Bullish Club Linked To Elon Musk